TNGX vs. SYRE, ETNB, OCUL, RCUS, AUPH, SPRY, ADPT, GYRE, MRVI, and PAHC
Should you be buying Tango Therapeutics stock or one of its competitors? The main competitors of Tango Therapeutics include Spyre Therapeutics (SYRE), 89bio (ETNB), Ocular Therapeutix (OCUL), Arcus Biosciences (RCUS), Aurinia Pharmaceuticals (AUPH), ARS Pharmaceuticals (SPRY), Adaptive Biotechnologies (ADPT), Gyre Therapeutics (GYRE), Maravai LifeSciences (MRVI), and Phibro Animal Health (PAHC). These companies are all part of the "pharmaceutical products" industry.
Tango Therapeutics vs.
Spyre Therapeutics (NASDAQ:SYRE) and Tango Therapeutics (NASDAQ:TNGX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, community ranking, valuation, earnings, dividends, analyst recommendations and risk.
Spyre Therapeutics has a net margin of 0.00% compared to Tango Therapeutics' net margin of -284.42%. Tango Therapeutics' return on equity of -49.64% beat Spyre Therapeutics' return on equity.
Tango Therapeutics received 10 more outperform votes than Spyre Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Spyre Therapeutics an outperform vote while only 73.68% of users gave Tango Therapeutics an outperform vote.
Tango Therapeutics has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Tango Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Spyre Therapeutics had 6 more articles in the media than Tango Therapeutics. MarketBeat recorded 7 mentions for Spyre Therapeutics and 1 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.96 beat Spyre Therapeutics' score of 0.53 indicating that Tango Therapeutics is being referred to more favorably in the news media.
80.4% of Spyre Therapeutics shares are held by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are held by institutional investors. 6.2% of Spyre Therapeutics shares are held by insiders. Comparatively, 6.3% of Tango Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Spyre Therapeutics has a beta of 2.85, meaning that its share price is 185% more volatile than the S&P 500. Comparatively, Tango Therapeutics has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500.
Spyre Therapeutics presently has a consensus target price of $54.83, indicating a potential upside of 157.55%. Tango Therapeutics has a consensus target price of $12.33, indicating a potential upside of 422.60%. Given Tango Therapeutics' higher possible upside, analysts clearly believe Tango Therapeutics is more favorable than Spyre Therapeutics.
Summary
Tango Therapeutics beats Spyre Therapeutics on 10 of the 18 factors compared between the two stocks.
Get Tango Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TNGX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tango Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:TNGX) was last updated on 2/22/2025 by MarketBeat.com Staff
